RELA (Ab-505) Antibody

What is the RELA (Ab-505) Antibody and what epitope does it recognize?

The Anti-Phospho-N kappa-p65 (T505) RELA Antibody (catalog # A00284T505) is a polyclonal antibody that specifically recognizes the phosphorylated threonine 505 residue of the human NF-kappaB p65 protein (RELA). This antibody was produced against a synthesized peptide derived from human NF-kappaB p65, specifically targeting the region surrounding the phosphorylation site at Thr505 (amino acid range: 471-520) . The specificity for this phosphorylation site makes it valuable for studying post-translational modifications in NF-κB signaling pathways.

Which species does the RELA (Ab-505) Antibody react with?

The Anti-Phospho-N kappa-p65 (T505) RELA Antibody has been validated to react with RELA protein from multiple species including Human, Mouse, and Rat . This cross-reactivity makes it suitable for comparative studies across these mammalian models, enabling researchers to investigate evolutionary conservation of NF-κB signaling mechanisms.

What are the validated applications for RELA (Ab-505) Antibody?

This antibody has been validated for the following applications:

• Enzyme-Linked Immunosorbent Assay (ELISA)

• Immunohistochemistry (IHC)

The manufacturer recommends specific dilution ranges for optimal results in these applications:

• IHC: 1:100-1:300

• ELISA: 1:5000

How should I optimize IHC protocols when using RELA (Ab-505) Antibody for tissue sections?

When optimizing IHC protocols with the RELA (Ab-505) Antibody, consider the following methodological approach:

• Fixation optimization: While standard formalin fixation works for many tissues, phospho-epitopes may require shorter fixation times (4-12 hours) to preserve phosphorylation status.

• Antigen retrieval: Test both heat-induced epitope retrieval (HIER) methods using citrate buffer (pH 6.0) and Tris-EDTA buffer (pH 9.0) to determine optimal conditions for exposing the phospho-Thr505 epitope.

• Blocking optimization: Use 5-10% normal serum from the same species as the secondary antibody plus 1% BSA to minimize background.

• Antibody dilution: Begin with the manufacturer's recommended range (1:100-1:300) and perform a dilution series to determine optimal signal-to-noise ratio for your specific tissue.

• Incubation conditions: Test both overnight incubation at 4°C and 1-2 hour incubation at room temperature to determine which provides better specific staining.

• Controls: Always include both a phosphatase-treated negative control (to confirm phospho-specificity) and a positive control tissue known to express phosphorylated RELA.

• Detection system: For low abundance phospho-proteins, consider using high-sensitivity detection systems like tyramide signal amplification.

What is the recommended protocol for detecting phospho-RELA in cell culture samples following stimulation?

For optimal detection of phosphorylated RELA following cell stimulation:

• Stimulation timing: Design a time-course experiment (0, 5, 15, 30, 60 minutes) to capture the kinetics of RELA phosphorylation at Thr505.

• Cell lysis: Use phosphatase inhibitor-enriched RIPA buffer (containing 50mM NaF, 5mM sodium pyrophosphate, 10mM β-glycerophosphate, and 1mM Na₃VO₄) to preserve phosphorylation status.

• Sample handling: Maintain samples on ice and process rapidly to minimize phosphatase activity.

• Protocol specifics for ELISA:

  • Coat plates with cell lysate or purified RELA protein

  • Block with 5% BSA in PBST

  • Apply Anti-Phospho-N kappa-p65 (T505) RELA Antibody at 1:5000 dilution

  • Incubate overnight at 4°C

  • Use appropriate HRP-conjugated secondary antibody

  • Develop with TMB substrate and read at 450nm

• Quantification: Always normalize phospho-RELA signals to total RELA protein levels to account for expression differences.

How can I use RELA (Ab-505) Antibody in combination with other antibodies for multiplex analysis of NF-κB pathway activation?

For advanced multiplex analysis of NF-κB signaling using RELA (Ab-505) Antibody:

• Sequential immunostaining approach:

  • Begin with the lowest abundance phospho-epitope (often p-RELA T505)

  • Use tyramide signal amplification with spectrally distinct fluorophores

  • Perform heat-mediated antibody stripping (glycine-HCl, pH 2.5, 50°C for 10 minutes)

  • Verify complete stripping with secondary antibody-only control

  • Proceed with next antibody in the sequence

• Complementary antibody selection:

  • Pair with antibodies against other NF-κB pathway components such as:

    • Phospho-IKKα/β

    • Phospho-IκBα

    • Other RELA phosphorylation sites (S536, S276)

    • c-Rel, p50, or p52 subunits

• Technical considerations:

  • Ensure antibodies are raised in different host species or use isotype-specific secondary antibodies

  • Validate each antibody individually before combining

  • Include appropriate controls for each detection channel

  • Consider spectral unmixing for highly overlapping fluorophores

• Data analysis approach:

  • Employ high-content imaging systems for quantitative analysis

  • Utilize colocalization analysis to assess spatial relationships between phosphorylated proteins

  • Apply machine learning algorithms for pattern recognition in complex signaling responses

What methods can address potential cross-reactivity concerns with RELA (Ab-505) Antibody?

To address cross-reactivity concerns and ensure signal specificity:

• Validation through competitive blocking:

  • Pre-incubate antibody with excess phosphorylated immunogenic peptide

  • Compare staining patterns with and without blocking peptide

  • Specific signals should be eliminated by peptide competition

• Phosphatase controls:

  • Treat duplicate samples with lambda phosphatase before immunostaining

  • Phospho-specific signals should be abolished in treated samples

  • Retain untreated controls for comparison

• Genetic validation approaches:

  • Use RELA knockout or knockdown models as negative controls

  • Employ site-directed mutagenesis (T505A) to validate phospho-specificity

  • Implement CRISPR-edited cell lines lacking the specific phosphorylation site

• Orthogonal detection methods:

  • Confirm findings using an alternative detection technology (mass spectrometry)

  • Employ phospho-specific detection using Phos-tag™ SDS-PAGE

  • Validate with a second antibody targeting a different epitope on the same protein

How can I address weak or inconsistent signals when using RELA (Ab-505) Antibody in IHC applications?

For troubleshooting weak or inconsistent IHC signals:

What are the critical factors affecting RELA phosphorylation detection in stimulation experiments?

Critical factors for successful phospho-RELA detection in stimulation experiments:

• Stimulation conditions:

  • Stimulus concentration and duration significantly impact phosphorylation kinetics

  • Cell confluence affects signaling efficiency (70-80% confluence typically optimal)

  • Serum starvation prior to stimulation reduces background phosphorylation

• Sample processing timing:

  • Rapid processing is essential as phosphorylation can be transient

  • Immediate lysis in cold, phosphatase inhibitor-containing buffer is critical

  • Avoid freeze-thaw cycles of phosphoprotein samples

• Technical parameters:

  • Maintain phosphatase inhibitor cocktail freshness

  • Buffer pH affects phospho-epitope stability

  • Temperature control during processing (keep samples cold)

• Experimental design considerations:

  • Include positive controls (known pathway activators like TNFα or IL-1β)

  • Implement time-course analysis to capture peak phosphorylation

  • Use multiple technical and biological replicates to account for variability

How can RELA (Ab-505) Antibody be integrated into high-throughput screening or single-cell analysis platforms?

For integration into advanced screening or single-cell platforms:

• High-throughput screening applications:

  • Adapt to automated immunofluorescence platforms in 384-well format

  • Optimize antibody concentrations for microfluidic chamber applications

  • Develop high-content imaging protocols focusing on nuclear translocation and phospho-RELA intensity

  • Create analysis pipelines that quantify both signal intensity and subcellular localization

• Single-cell analysis integration:

  • Modify protocols for compatibility with mass cytometry (CyTOF) using metal-conjugated antibodies

  • Optimize for imaging mass cytometry to preserve spatial information

  • Develop flow cytometry protocols with appropriate permeabilization for intracellular phospho-epitopes

  • Implement the following fixation/permeabilization strategy:

    • 2% paraformaldehyde fixation (10 minutes)

    • Methanol permeabilization (-20°C, 30 minutes)

    • Gradual rehydration to preserve epitope accessibility

• Spatial analysis platforms:

  • Optimize for multiplexed ion beam imaging (MIBI)

  • Adapt protocols for digital spatial profiling platforms

  • Develop sequential immunofluorescence cycling methods for highly multiplexed tissue analysis

• Data integration approaches:

  • Combine phospho-RELA signal with transcriptomic data for pathway activity correlation

  • Implement machine learning algorithms for pattern recognition across large datasets

  • Develop visualization tools for multi-parameter data representation

What considerations are important when using RELA (Ab-505) Antibody for mechanistic studies of non-canonical NF-κB signaling?

For mechanistic studies of non-canonical NF-κB signaling:

• Pathway-specific considerations:

  • The Thr505 phosphorylation site may have distinct regulation in canonical versus non-canonical pathways

  • Design experiments to specifically activate non-canonical signaling (e.g., using LIGHT, CD40L, or LTβR agonists)

  • Include time points extending to 24-48 hours to capture slower non-canonical activation kinetics

• Key control experiments:

  • Compare RELA Thr505 phosphorylation patterns between canonical (TNFα) and non-canonical stimuli

  • Include inhibitors specific to each pathway arm:

    • IKKβ inhibitors (for canonical pathway)

    • NIK inhibitors (for non-canonical pathway)

  • Monitor processing of p100 to p52 as confirmation of non-canonical activation

• Experimental design matrix:

  • Create a comprehensive stimulation grid varying:

    • Stimulus type (canonical vs. non-canonical activators)

    • Inhibitor combinations

    • Time course sampling

    • Cell types with varying non-canonical component expression

• Advanced analytical approaches:

  • Employ proximity ligation assays to detect interactions between phospho-RELA and non-canonical pathway components

  • Perform ChIP-seq with the RELA (Ab-505) Antibody to identify binding sites specific to non-canonical stimulation

  • Correlate phosphorylation status with functional outcomes (gene expression, cell survival)

How can computational approaches enhance the analysis of data generated using RELA (Ab-505) Antibody?

Advanced computational approaches for phospho-RELA data analysis:

• Spatio-temporal modeling:

  • Develop cellular compartment segmentation algorithms to track phospho-RELA movement

  • Apply mathematical modeling to quantify nuclear-cytoplasmic shuttling dynamics

  • Implement reaction-diffusion models to understand phosphorylation propagation within cells

• Machine learning applications:

  • Train neural networks to identify subtle patterns in phospho-RELA distribution

  • Apply clustering algorithms to identify cell subpopulations based on phosphorylation profiles

  • Develop predictive models for cellular responses based on early phosphorylation events

• Network analysis integration:

  • Map phospho-RELA signals onto known protein-protein interaction networks

  • Integrate phosphoproteomic data with transcriptomic responses

  • Develop pathway enrichment methods specific to phosphorylation-dependent processes

• Image analysis advancements:

  • Implement deep learning for automated quantification of IHC/IF images

  • Develop algorithms for tissue-specific normalization of phospho-signals

  • Create visualization tools for multi-dimensional phosphorylation data across tissue sections

What are the emerging applications of RELA (Ab-505) Antibody in understanding disease mechanisms?

Emerging applications in disease mechanism research:

• Neurodegenerative disease applications:

  • Investigate the role of RELA Thr505 phosphorylation in neuroinflammatory processes

  • Examine correlations between phospho-RELA patterns and disease progression in tissue microarrays

  • Study cell type-specific phosphorylation in complex brain tissues using multiplexed imaging

• Cancer research applications:

  • Analyze phospho-RELA T505 status across cancer progression stages

  • Correlate with treatment resistance phenotypes

  • Investigate as a potential biomarker for targeted therapy response

• Immunological disorder research:

  • Examine phosphorylation patterns in autoimmune disease tissues

  • Correlate with disease activity scores in inflammatory conditions

  • Study the impact of biologic therapies on phospho-RELA signaling

• Methodological integration in clinical research:

  • Develop tissue-based companion diagnostic approaches

  • Create standardized reporting guidelines for phospho-epitope analysis

  • Implement digital pathology tools for quantitative assessment across patient cohorts